Treatment of essential hypertension.
While no consensus over the treatment of essential hypertension has been reached, three recent major trials offer guidance to the clinician. The results of these trials and the role of new and old drugs in the treatment of hypertension are discussed.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004232:Diuretics; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage; D013722:Teprotide
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D009842:Oligopeptides; D049993:Sodium Chloride Symporter Inhibitors; D013722:Teprotide